NIH R01 · 2025
Epac1 as a novel therapeutic target for diabetic retinopathy
Each year, millions of Americans face vision loss related to diabetes. According to the U.S. Centers for Disease Control and Prevention, more than 30 million Americans have diabetes, and a third of diabetics aged 40 or over in the U.S. have diabetic retinopathy (DR) and related diabetic eye diseases. While the pathogenic mechanisms underpinning the development of DR appear multifactorial and remain incompletely understood, abnormal neovascularization is a key contributing factor, supported by the fact that therapy with anti-VEGF (vascular endothelial growth factor) drugs has become the gold standard treatment for DR and its complications among other interventions. Whilst anti-VEGFs…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.